Medical technology company Medovex recently sent a shareholder letter addressing company issues and progress with the patented DenerveX device for treating facet joint pain.
The company's letter passed along information to keep shareholders on top of decisions made toward previously stated goals. The company recently went public on the NASDAQ.
Here are five key points from the letter:
1. DenerveX's progress for treating patients with spinal degenerative issues.
2. The device is single-use for less invasive procedures with a faster recovery time than the currently used surgical treatment.
3. The DenerveX system also offers potential saving s to the healthcare system.
4. Medovex's distribution strategy in the United States, Europe and Asia Pacific focuses on distribution partners with experience and access to top 100 institutions in addition to other connections.
5. The company is looking for a new pipeline product for development.